Prophylactic vaccine for visceral leishmaniasis
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $25,000 to $250,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- Points of contact
-
- tbd@fda.gov
- Joshua Holliday joshua.holliday@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Department of Health and Human Services Food and Drug Administration is seeking a prophylactic vaccine for visceral leishmaniasis, with an estimated solicitation release date of July 1, 2026, and an anticipated contract award date of September 1, 2026. This procurement falls under the Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers NAICS code 423450, indicating a focus on medical supply and vaccine development. The contract aims to develop a preventative vaccine for visceral leishmaniasis, a potentially serious parasitic disease.
The primary point of contact for this opportunity is Joshua Holliday, who can be reached at joshua.holliday@fda.hhs.gov within the FDA organization. While specific award values and budget ranges are not currently available, the contract appears to be open to all potential vendors with no specific set-aside provisions. Interested contractors should note the December 10, 2025 posting date and prepare for potential solicitation release in mid-2026, with a contract award expected in early fall of the same year.
Forecast text
Prophylactic vaccine for visceral leishmaniasis
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast